Guía clínica sobre el cáncer de testículo de la EAU
Standard
Guía clínica sobre el cáncer de testículo de la EAU : actualización de 2011. / Albers, P; Albrecht, W; Algaba, F; Bokemeyer, C; Cohn-Cedermark, G; Fizazi, K; Horwich, A; Laguna, M P; European Association of Urology.
In: ACTAS UROL ESP, Vol. 36, No. 3, 01.03.2012, p. 127-45.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Guía clínica sobre el cáncer de testículo de la EAU
T2 - actualización de 2011
AU - Albers, P
AU - Albrecht, W
AU - Algaba, F
AU - Bokemeyer, C
AU - Cohn-Cedermark, G
AU - Fizazi, K
AU - Horwich, A
AU - Laguna, M P
AU - European Association of Urology
N1 - Copyright © 2011 AEU. Published by Elsevier Espana. All rights reserved.
PY - 2012/3/1
Y1 - 2012/3/1
N2 - CONTEXT: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy, and follow-up of testicular cancer were established.OBJECTIVE: This article is a short version of the EAU testicular cancer guidelines and summarises the main conclusions from the guidelines on the management of testicular cancer.EVIDENCE ACQUISITION: Guidelines were compiled by a multidisciplinary guidelines working group. A systematic review was carried out using Medline and Embase, also taking Cochrane evidence and data from the European Germ Cell Cancer Consensus Group into consideration. A panel of experts weighted the references, and a level of evidence and grade of recommendation were assigned.RESULTS: There is a paucity of literature especially regarding longer term follow-up, and results from a number of ongoing trials are awaited. The choice of treatment centre is of the utmost importance, and treatment in reference centres within clinical trials, especially for poor-prognosis nonseminomatous germ cell tumours, provides better outcomes. For patients with clinical stage I seminoma, based on recently published data on long-term toxicity, adjuvant radiotherapy is no longer recommended as first-line adjuvant treatment. The TNM classification 2009 is recommended.CONCLUSIONS: These guidelines contain information for the standardised management of patients with testicular cancer based on the latest scientific insights. Cure rates are generally excellent, but because testicular cancer mainly affects men in their third or fourth decade of life, treatment effects on fertility require careful counselling of patients, and treatment must be tailored taking individual circumstances and patient preferences into account.TAKE HOME MESSAGE: Although testicular cancer has excellent cure rates, the choice of treatment centre is of the utmost importance. Expert centres achieve better results for both early stage testicular cancer (lower relapse rates) and overall survival (higher stages within clinical trials). For patients with clinical stage I seminoma, adjuvant radiotherapy is no longer recommended as first-line adjuvant treatment.
AB - CONTEXT: On behalf of the European Association of Urology (EAU), guidelines for the diagnosis, therapy, and follow-up of testicular cancer were established.OBJECTIVE: This article is a short version of the EAU testicular cancer guidelines and summarises the main conclusions from the guidelines on the management of testicular cancer.EVIDENCE ACQUISITION: Guidelines were compiled by a multidisciplinary guidelines working group. A systematic review was carried out using Medline and Embase, also taking Cochrane evidence and data from the European Germ Cell Cancer Consensus Group into consideration. A panel of experts weighted the references, and a level of evidence and grade of recommendation were assigned.RESULTS: There is a paucity of literature especially regarding longer term follow-up, and results from a number of ongoing trials are awaited. The choice of treatment centre is of the utmost importance, and treatment in reference centres within clinical trials, especially for poor-prognosis nonseminomatous germ cell tumours, provides better outcomes. For patients with clinical stage I seminoma, based on recently published data on long-term toxicity, adjuvant radiotherapy is no longer recommended as first-line adjuvant treatment. The TNM classification 2009 is recommended.CONCLUSIONS: These guidelines contain information for the standardised management of patients with testicular cancer based on the latest scientific insights. Cure rates are generally excellent, but because testicular cancer mainly affects men in their third or fourth decade of life, treatment effects on fertility require careful counselling of patients, and treatment must be tailored taking individual circumstances and patient preferences into account.TAKE HOME MESSAGE: Although testicular cancer has excellent cure rates, the choice of treatment centre is of the utmost importance. Expert centres achieve better results for both early stage testicular cancer (lower relapse rates) and overall survival (higher stages within clinical trials). For patients with clinical stage I seminoma, adjuvant radiotherapy is no longer recommended as first-line adjuvant treatment.
KW - Algorithms
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Cancer Care Facilities
KW - Chemotherapy, Adjuvant
KW - Combined Modality Therapy
KW - Diagnostic Imaging
KW - Disease Management
KW - Evidence-Based Medicine
KW - Humans
KW - Lymph Node Excision
KW - Male
KW - Neoplasm Staging
KW - Neoplasms, Germ Cell and Embryonal
KW - Orchiectomy
KW - Organ Sparing Treatments
KW - Prognosis
KW - Radiotherapy, Adjuvant
KW - Salvage Therapy
KW - Sex Cord-Gonadal Stromal Tumors
KW - Societies, Medical
KW - Testicular Neoplasms
KW - Treatment Outcome
KW - Tumor Markers, Biological
U2 - 10.1016/j.acuro.2011.06.017
DO - 10.1016/j.acuro.2011.06.017
M3 - SCORING: Zeitschriftenaufsatz
C2 - 22188753
VL - 36
SP - 127
EP - 145
JO - ACTAS UROL ESP
JF - ACTAS UROL ESP
SN - 0210-4806
IS - 3
ER -